Quantum Immunologics, Inc. Announces Appointment of Dr. George Peoples to Scientific Advisory Board

TAMPA, FL--(Marketwire - December 20, 2010) -

Highlighted Links

www.quantumimmunologics.com

Quantum Immunologics, Inc. ("QI"), a Tampa, FL-based company currently engaged in an FDA-authorized clinical study of its autologous dendritic cell immunotherapy for Stage IV breast cancer patients, is pleased to announce the appointment of Dr. George E. Peoples, M.D., of Brooke Army Medical Center, San Antonio, TX to QI's Scientific Advisory Board ("SAB"). Dr. Kent Johnson, QI's Chief Science Officer, successfully engaged Dr. Peoples as an Advisory Board Member.

Dr. Johnson stated: "The appointment of Dr. Peoples represents a significant milestone in development of our clinical programs at Quantum. Dr. Peoples has had extensive experience in overseeing clinical trials including those with cancer vaccines such as ours and his expertise will be invaluable moving forward in clinical development. We look forward to working with Dr. Peoples on this important phase of drug development."

Quantum Immunologics is dedicated to the research, development and production of products and services that will promote unique, individualized immunologic cancer treatment and early detection technologies.

Dr. Peoples stated: "I am excited by the opportunity to assist Quantum with their clinical development program as we share the belief that the recruitment of the patient's own immune system will be the next critical advance in the treatment of cancer."

About Dr. George Peoples
Dr. Peoples graduated from West Point in 1984 and from Johns Hopkins School of Medicine in 1988. After a surgical internship at Walter Reed Army Medical Center (WRAMC), he completed his surgical training at the Brigham and Women's Hospital in Boston, MA in 1996. During that time, Dr. Peoples also completed a research fellowship at the Laboratory of Biologic Cancer Therapy at Harvard Medical School. He then completed a surgical oncology fellowship at MD Anderson Cancer Center in Houston, TX in 1998. He served as the Chief of Surgical Oncology at WRAMC from 1998-2006, and currently serves in the same position at Brooke Army Medical Center. Additionally, he serves as the Director of the Cancer Vaccine Development Program and the Deputy Director of the United States Military Cancer Institute. He is the PI on several multi-center cancer vaccine clinical trials being conducted nationally and internationally and has written extensively on the immune response to cancer.

About Quantum Immunologics
Quantum Immunologics is dedicated to the research, development and production of products and services that will promote unique, individualized immunologic cancer treatment and early detection technologies with a high rate of efficacy, minimal side effects and greatly reduced cost compared to current treatments.

Quantum Immunologics has received FDA authorization to apply its exclusively licensed immunotherapy technology in a Phase I/II human clinical study. QI's Phase I/II clinical trial, which involves a cohort of 27 patients with advanced-stage metastatic breast cancer, is designed around the use of QI's proprietary dendritic cell therapy, which employs the oncofetal antigen/immature laminin receptor protein ("OFA/iLRP") to recruit the patient's own immune system to target the cancer cells with the goal of improving patient survivability and quality of life.

Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include, but are not limited to, statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Quantum Immunologics, Inc. undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.